Target Therapeutics expects to complete GDC recall in two weeks.
This article was originally published in The Gray Sheet
Executive Summary
TARGET THERAPEUTICS GUGLIELMI DETACHABLE COIL RECALL expected to be completed within two weeks, the company says. The recall of two lots of the GDC coils was initiated the week of July 29 following receipt of a complaint the previous week "related to difficulty in the fluoroscopic visualization of the marker on the delivery wires" of certain lots of the GDC device, the company says in a July 30 release. The action affects less than 5% of GDC inventory in domestic and overseas hospitals, Target estimates.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.